Background {#Sec1}
==========

Ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) have been established as useful tools in the multimodality approach to detect, characterize, and diagnose ovarian tumors \[[@CR1]\]. Ultrasonography is advantageous, compared with CT and MRI, due to its accessibility as a first-line imaging examination, which is painless and relatively inexpensive compared with CT and MRI. However, MRI offers the following potential advantages compared with the other modalities: lack of ionizing radiation exposure relative to CT, higher contrast resolution, higher specificity, greater accuracy, more reliable and reproducible measurements, and good inter-observer agreement for identification of malignant ovarian lesions \[[@CR2]\]. The accuracies of ovarian cancer patient diagnosis with ultrasonography, CT, and MRI are 84--89%, 82--88%, and 88--93%, respectively \[[@CR3]--[@CR7]\].

Several studies have investigated the diagnostic value of various MRI sequences, including T1-weighted, T2-weighted, T1-weighted with fat suppression and contrast, diffusion-weighted (DW) MRI, and dynamic contrast-enhanced MRI, in the evaluation of benign and malignant ovarian lesions \[[@CR8]--[@CR10]\]. Characteristic features of epithelial ovarian cancer include the presence of the following: a cystic mixed mass (complex solid and cystic), varying proportions of a solid-enhancing component, a mural nodule or papillary projection and internal thick septation, central necrosis, tumor vascularity, ascites, peritoneal implants, and lymph node enlargement \[[@CR10], [@CR11]\].

Epithelial ovarian cancers are classified as one of two types: type I includes patients with low-grade serous carcinoma, low-grade endometrioid carcinoma (EC), clear cell carcinomas (CCC), mucinous carcinoma, Brenner tumors, and slow-growing tumors; and type II includes patients with rapidly growing high-grade serous carcinoma (HGSC), high-grade endometrioid carcinoma, undifferentiated carcinomas, and highly aggressive malignancies \[[@CR12]\]. CCC and EC are the most common types of ovarian cancer highly associated with endometriosis \[[@CR13]\]. The size of ovarian endometrioma (tumor size ≥9 cm), multiple foci of endometriosis, and presence of tumors with solid components or mural nodules, are risk factors that are likely associated with malignant transformation of endometriosis \[[@CR14]--[@CR16]\]. CCC is the second most common histologic subtype (27.6%) of epithelial ovarian cancer in Japan \[[@CR17], [@CR18]\]. Compared with its incidence in Caucasians, CCC is more common in Asians \[[@CR19]\]. There is a substantial difference between type I and type II epithelial ovarian cancers in terms of the MRI morphological features \[[@CR20], [@CR21]\]. The imaging characteristics of type I tumors frequently include the presence of a predominantly cystic mass, a larger lesion, mural nodules, papillary architecture, and strong enhancement, relative to those aspects in type II tumors \[[@CR10]\].

It is important to distinguish between CCC and EC because CCC is associated with a poor prognosis, based on its chemoresistant phenotype. However, MRI findings, such as tumor size, fluid signal intensity, post-contrast enhancement pattern, and mean apparent diffusion coefficient values of the solid portion, may not be useful parameters for differentiating CCC from EC \[[@CR22]\]. Manabe et al. reported that the presence of endometrial disease was a key factor in differentiating EC from CCC \[[@CR23]\]. Another MRI morphological feature of EC comprised an internal slit in the solid components \[[@CR23]\]. Thus far, very few studies have evaluated the usefulness of morphological features in the differential diagnosis of CCC and EC. It is unclear whether reliable predictors for recognizing type I and type II tumors may comprise useful tools to differentiate CCC from EC.

The purpose of this retrospective study was to assess preoperative MRI characteristics useful for distinguishing between CCC and EC.

Methods {#Sec2}
=======

Study cohort {#Sec3}
------------

This study was approved by the institutional review board of Nara Medical University. Written informed consent was obtained from each patient. The inclusion criteria were as follows: the medical records of patients with CCC and EC who underwent surgical treatment at Nara Medical University Hospital between January 2008 and September 2018 were reviewed. Tumor staging I-IV was performed in accordance with the FIGO classification. A baseline MRI scan was obtained for all patients before any intervention. Contrasted MRI scans were performed less than 2 months before surgery. Patients were excluded from the study if they had no pathology, other pathological subtype of epithelial ovarian cancer, and/or salvage treatment for recurrence and metastatic ovarian cancer at study initiation. One radiologist and one gynecologic oncologist with 10--20 years of experience independently reviewed the MR images of all patients; these reviewers were blinded to the clinical and histopathologic data. This study included 98 patients who met the inclusion and exclusion criteria (primary CCC (*n* = 52) and EC (*n* = 46)).

Data collection {#Sec4}
---------------

Data were collected from all enrolled patients and were compared between the two groups. Assessments included baseline characteristics such as age, BMI, parity, and menopausal status.

Imaging technique {#Sec5}
-----------------

MRI scans were performed on a 3.0 Tesla system (Magnetom Verio; Siemens Healthcare, Erlangen, Germany) with a 32-element body array coil. The protocol of our MRI examination was performed as described previously \[[@CR24]\]. MRI scans were T1-weighted, T2-weighted, T1-weighted with fat suppression and gadolinium-enhanced, and DW.

Imaging features {#Sec6}
----------------

The following MRI morphologic features were assessed with both T1 and T2 phases, such as the maximal diameter of the cyst, tumor margin, multilocularity, growth patterns and surface irregularities of mural nodules, characteristics of solid components, and the presence of malignant ascites; all of these features are considered significant factors in distinguishing between benign and malignant ovarian tumors \[[@CR23], [@CR24]\]. A mural nodule was defined as a wall-based lesion projecting into the cystic space. Several variables involving mural nodules were selected in this study. As described previously, we defined the size of a mural nodule according to its "Height" and "Width" \[[@CR24]\]. The term "Height" indicated maximum vertical length from the bottom of the cyst to the top of the nodule. The term "Width" indicated maximum perpendicular length to the "Height." For each case, the largest dimensions of mural nodules were used to determine "Height" and "Width." Mural nodular HWR was also calculated. The appearances of tumor margins were classified into two types: a well-defined margin (clear-cut margin) or an ill-defined margin (uncertain margin). The growth pattern of the mural nodules or solid components was designated as one of two categories. The mural nodules were either broad-based nodular structures or polypoid structures. When more than three solid components existed along the inner cystic surface, the pattern was defined as "multifocal, concentric, or broad-based nodular structures" \[[@CR23]\]. If one or two mural nodules existed on the inner surface of the cyst, the pattern was defined as "focal, eccentric, or polypoid structures." When the mural nodules arose from more than one-third of the tumor wall, the pattern was defined as "continuing." The surface irregularity pattern of the mural nodules or solid components was also divided into two categories: a smooth or regular surface; or a rough, irregular, or lobulated surface. The degree of ascites was graded by using standard criteria, as either negative or positive.

Statistical analyses {#Sec7}
--------------------

Statistical analyses were performed using JMP software (version 5.0; SAS Institute Inc., Cary, NC, USA). Independent samples t-test (normality) or Mann--Whitney U test (non-normality) methods were used to compare variables between CCC and EC. Variables that were significant in univariate analyses (*p* \< 0.05) were used in the multivariate logistic regression model. Survival analyses were performed using the Kaplan--Meier method and log-rank test.

Results {#Sec8}
=======

Patient demographic factors and tumor characteristic factors {#Sec9}
------------------------------------------------------------

Patient demographic factors of the study population are summarized in Table [1](#Tab1){ref-type="table"}. All patients were of Japanese ethnicity. There were no significant differences between the CCC and EC groups in variables such as age, body mass index (BMI), parity, menopausal status, clinical stage, or International Federation of Gynecology and Obstetrics (FIGO) stage (postsurgical stage). The imaging findings associated with tumor characteristics on MRI were compared between the two groups via univariate analysis (Table [2](#Tab2){ref-type="table"}). There were no significant differences between the CCC and EC groups in variables such as the maximum diameter of the cyst, ill-defined margin, or locularity.Table 1Patient characteristics of the two groupsCCC (n = 52)EC (*n* = 46)*p* valueAge at diagnosis Mean ± SD56.05 ± 11.6255.76 ± 10.260.894 Median (range)55.0 (36--90)54.5 (31--77)BMI (kg/m^2^) Mean ± SD22.46 ± 3.6922.76 ± 4.320.713 Median (range)22.0 (15.4--32.8)21.9 (11.7--32.4)Parity Multipara37280.282 Nullipara1518Menopausal status Premenopause19150.683 Postmenopause3331clinical stage I / II42330.265 III / IV1013FIGO stage (postsurgical stage) I / II43340.290 III / IV912*BMI* body mass index, *FIGO* International Federation of Gynecology and Obstetrics, *SD* standard deviation, *CCC* clear cell carcinoma, *EC* endometrioid carcinomaTable 2Fisher's exact test for univariate analysis of the two groupsCCCECOR95% CI*p* valueMaximum diameter of the cyst  \< 17.8 (cm)45340.480.162--1.3500.171  ≥ 17.8 (cm)711Height of mural nodule  \< 4.0 (cm)37270.550.219--1.3360.188  ≥ 4.0 (cm)1216Width of mural nodule  \< 5.8 (cm)41220.200.074--0.5200.0013  ≥ 5.8 (cm)821HWR  \< 0.6914263.951.665--9.7600.0022  ≤ 0.693416Growth pattern of mural nodules Focal or eccentric3040.070.019--0.204\< 0.0001 Multifocal or concentric2242Continuity of mural nodules Negative36170.260.110--0.5940.0017 Positive1629Appearance of mural nodule margins Smooth1850.230.070--0.6450.0083 Not smooth3441Absence of ascites Negative33170.340.146--0.7590.0097 Positive1929*CCC* clear cell carcinoma, *EC* endometrioid carcinoma, *OR* odds ratio, *CI* confidence interval

On univariate analysis, six variables, such as the "Width," "Height-to-Width" ratio (HWR), growth pattern, and surface irregularity of mural nodules, as well as the presence of ascites and continuity of mural nodules, were significant factors for prediction of CCC. The mural nodule "Width" in patients with EC was statistically significant, compared with that width in patients with CCC (5.42 ± 2.14 cm versus 3.91 ± 1.93 cm, *p* = 0.0013). The patients with EC, when compared with those with CCC, had a smaller HWR (0.69 ± 0.41 cm versus 0.91 ± 0.50 cm, *p* = 0.0022). The multifocal, concentric, or broad-based nodular structures were observed in 29 (63.0%) of 46 patients with EC and 16 (30.7%) of 52 patients with CCC (*p* = 0.0017). Compared with CCC, the mural nodule was significantly wider and more multifocal in EC. Twenty-nine patients (63.0%) with EC showed a continuing mural nodule pattern, whereas 16 patients (38.1%) with CCC showed the continuing pattern (p = 0.0017). Among the 98 patients with EAOC, 50 were classified as "negative" and 48 as "positive," respectively. Among all patients, 36.5% (19/52) and 63.0% (29/46) had ascites in CCC and EC, respectively (*p* = 0.0097). A round and polypoid mass with high HWR, as well as the absence of ascites, were findings significantly associated with CCC.

Figure [1](#Fig1){ref-type="fig"} shows the typical imaging appearances of CCC (A) and EC (B). MRI diagnosis of CCC and EC comprised a large unilocular or multilocular cystic mass associated with several mural nodules protruding into the cystic space. The following imaging characteristics may be aid in diagnosis of CCC: a large cystic mass with a small mural nodule, representing a focal, eccentric, or polypoid growth pattern. In contrast, EC mural nodules exhibited a large, heterogenous mixed mass, representing a multifocal, concentric, or broad-based nodular growth pattern.Fig. 1MRI features typical of CCC (**a**) and EC (**b**) lesions. T2-weighted MRI shows examples of CCC mural nodules with a focal, eccentric, or polypoid structure pattern (**a**) and EC mural nodules with a multifocal, concentric, or broad-based nodular pattern (**b**). The multifocal or concentric pattern shows the continuity of each mural nodule. MRI, magnetic resonance imaging; CCC, clear cell carcinoma; EC, endometrioid carcinoma

Multivariate logistic regression model {#Sec10}
--------------------------------------

All variables showing significant values in the univariate analysis were included in the multivariate analysis. Multivariate logistic regression analysis revealed that HWR and the growth pattern of the mural nodules resulted in the best discrimination of patients with CCC from those with EC (Table [3](#Tab3){ref-type="table"}). Receiver operating characteristic (ROC) curves showed that the area under the curve (AUC), 95% confidence interval (CI), optimum diagnostic cutoff value, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) predicted CCC. The AUC for HWR was 0.706 (95% CI: 0.263--0.609), followed by 0.677 (95% CI: 0.286--0.769) for "Width" of a mural nodule (Table [4](#Tab4){ref-type="table"}). The focal growth pattern yielded a sensitivity of 91.3% (95% CI, 82.4--96.4%), specificity of 57.7% (95% CI, 49.8--62.2%), PPV of 65.6% (95% CI, 59.2--69.3%), and NPV of 88.2% (95% CI 76.1--95.1%). The HWR yielded a sensitivity of 70.8% (95% CI, 61.3--79.1%), specificity of 61.9% (95% CI, 51.0--71.4%), PPV of 68.0% (95% CI, 58.8--76.0%), and NPV of 65.0% (95% CI 53.5--74.9%). The focal growth pattern of mural nodules demonstrated a higher HWR for diagnostic sensitivity and improved predictive values for negative test results.Table 3Multivariate logistic regression analysis for the prediction of clear cell carcinomaStandard errorWaldOR95% CI*p* valueWidth of mural nodule0.3530.3250.670.165--2.6950.568HWR0.3124.4223.711.128--13.4380.036Growth pattern of mural nodule0.38012.3990.690.013--0.2730.0004Continuity of mural nodules0.3450.3200.680.173--2.6650.572Appearance of mural nodule margins0.3860.0850.800.170--3.7200.770Absence of ascites0.2860.3930.700.229--2.1970.531*OR* odds ratio, *CI* confidence interval, *HWR* Height-to-Width ratioTable 4Discriminative value of each parameterAUC95% CI*p* valuecutoff valuesensitivityspecificityPPVNPVMaximum diameter of the cyst0.504−0.690-1.2650.57317.8 (cm)0.2440.86561.157.0Height of mural nodule0.540−0.738-1.2680.6114.0 (cm)0.3720.75557.157.8Width of mural nodule0.6770.595--2.7880.0035.8 (cm)0.4880.83772.465.0HWR0.706−2.001-0.1510.0620.690.6910.66764.471.1*AUC* area under the curve, *CI* confidence interval, *PPV* positive predictive value, *NPV* negative predictive value, *HWR* Height-to-Width ratio

Survival {#Sec11}
--------

The 5-year survival rates of patients with CCC and EC were 89.5 and 76.5% (*p* = 0.381). There were no differences in survival between CCC and EC.

Discussion {#Sec12}
==========

In the present study, we aimed to identify the preoperative MRI characteristics that could aid in distinguishing CCC from EC. Both tumors were a large unilocular or multilocular cystic masses associated with several mural nodules protruding into the cystic space. On univariate analysis, the absence of ascites (*p* = 0.0097), a polypoid mural nodule structure (*p* \< 0.0001), a smooth rather than lobulated mural nodule surface (*p* = 0.0083), and high HWR (*p* = 0.0022) served as predictors for differentiating CCC from EC. After multivariate analysis, a polypoid mural nodule structure (*p* = 0.0004) and HWR (*p* = 0.036) remained strong and independent predictors.

First, conventional MRI could aid in distinguishing endometriosis-associated ovarian cancer (EAOC) from HGSC \[[@CR18]\]. EAOC rarely showed low-signal intensity on T2-weighted images and typically exhibited enhanced mural nodules \[[@CR18], [@CR19], [@CR25]\]. The signal intensity on T1-weighted imaging varies from low to very high in CCC \[[@CR25]\] and demonstrates homogeneous iso- or hyperintensity in EC \[[@CR19]\], suggesting that MR imaging findings on intratumoral cystic components were similar between CCC and EC. The following characteristics were significantly more common for EC than for HGSC: unilateral, round or oval shape, larger mass, mainly cystic with mural nodules or papillary projections, mild ascites, and synchronous primary cancer of the ovary and endometrium \[[@CR19]\]. Furthermore, compared with HGSC, the MRI features of CCC were unilateral, unilocular, oval shape, larger mass, mainly cystic with mural nodules or papillary projections, fewer peritoneal implants, and no or mild ascites \[[@CR18], [@CR26]\]. Therefore, these two groups exhibited many similar imaging features.

Second, based on these backgrounds, we aimed to identify preoperative imaging characteristics that could assist in the differential diagnosis between CCC and EC. Many cases of malignant mural nodule have been reported in epithelial ovarian cancer \[[@CR18], [@CR19], [@CR25]\]; however, the previous studies rarely focused on the MRI features of CCC and EC. Six variables, such as the "Width," HWR, growth pattern, and surface irregularity of mural nodules, as well as the presence of ascites and continuity of mural nodules, were significant factors for differentiating CCC from EC, according to the univariate analysis. A previous study examined MRI features in nine patients with CCC; it revealed that approximately 90% of CCC lesions showed focal mural nodules \[[@CR23]\], a rate much higher than that observed in our study. We found that CCC mural nodules had more focal, eccentric, and polypoid structures (vs. multifocal, concentric, and broad-based nodular structures) than EC (57.7% vs. 8.2%, *p* \< 0.0001). On multivariate analysis, HWR and growth pattern of mural nodule remained a strong and independent predictor. Our data indicated that the MRI findings of CCC and EC often overlapped.

Finally, we briefly discuss why CCC predominantly shows a focal, eccentric, or polypoid structure pattern, whereas EC shows a multifocal, concentric, or broad-based nodular structure pattern in the growth of mural nodules. A previous study demonstrated that gene expression profiling could stratify endometriosis into two molecular subtypes: transcription factor hepatocyte nuclear factor 1-beta (HNF-1β)-positive (hypomethylated) and -negative (hypermethylated) cells \[[@CR27]\]. Approximately 40% of benign endometriotic cysts expressed HNF-1β \[[@CR27]\]. HNF-1β is specifically upregulated in CCC, but not in EC, suggesting that HNF-1β is a key molecule in endometriosis-associated clear cell carcinogenesis and progression \[[@CR28]\]. CCC and adjacent atypical endometriosis had HNF-1β overexpression, while benign endometriosis distant from CCC showed negative immunoreactivity for HNF-1β \[[@CR29]\]. HNF-1β has been demonstrated as a positive modulator in the survival and growth of CCC cells \[[@CR30]\]. CCC cells that arise from HNF-1β positive pre-malignant endometriotic cells would form lesions with focal, eccentric, and polypoid mural nodule structures. In contrast, EC is characterized by epigenetic changes, including considerable estrogen receptor (ER) expression, and could share common estrogen-dependent oncogenic pathways \[[@CR29]\]. Up-regulation of ER expression is commonly shared by benign endometriosis, atypical endometriosis, and EC, which may denote a carcinogenic potential in entire areas of endometriotic lesion; this could explain the synchronous and multifocal growth pattern of EC \[[@CR29]\]. Notably, EC may comprise an intratumoral metastasis arising from a primary focal EC. The different molecular profiles observed here are likely to contribute to the predominant focal pattern of mural nodule growth in CCC, while EC exhibits a multifocal pattern.

This study had several limitations. First, it was a retrospective study; therefore, there may have been some selection bias in the patients included in the analyses. Second, imaging features were evaluated in a limited number of patients, all of whom were of Japanese ethnicity.

Conclusions {#Sec13}
===========

Here, we revealed that the MRI findings of CCC and EC often overlapped; however, morphological features (e.g., a round mural nodule with high HWR and a focal growth pattern) are useful to distinguish CCC from EC. These potential features may aid clinicians in effective diagnosis. Because this study included only Japanese patients, our conclusions may not apply to patients of other ethnicities. Much work is needed to explore new approaches with high sensitivity and specificity for discriminating CCC and EC.
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